moioci

It's a research letter, not a full article. Accordingly, there's no abstract. They just show the first of 11 paragraphs as a teaser.

from clinicaltrials.gov:

Eligibility Criteria

Key Inclusion Criteria:

Resectable cutaneous melanoma metastatic to a lymph node and at high risk of recurrence

Complete resection within 13 weeks prior to the first dose of pembrolizumab

Disease free at study entry (after surgery) with no loco-regional relapse or distant metastasis and no clinical evidence of brain metastases

Has an formalin fixed paraffin embedded (FFPE) tumor sample available suitable for sequencing

Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

Normal organ and marrow function reported at screening

Key Exclusion Criteria:

Prior malignancy, unless no evidence of that disease for at least 5 years prior to study entry

Prior systemic anti-cancer treatment (except surgery and interferon for thick primary melanomas. Radiotherapy after lymph node dissection is permitted)

Live vaccine within 30 days prior to the first dose of pembrolizumab

Transfusion of blood or administration of colony stimulating factors within 2 weeks of the screening blood sample

Active autoimmune disease

Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab

Solid organ or allogeneic bone marrow transplant

Pneumonitis or a history of (noninfectious) pneumonitis that required steroids

Prior interstitial lung disease

Clinically significant heart failure

Known history of human immunodeficiency virus (HIV)

Known active hepatitis B or C

Active infection requiring treatment

Ages Eligible for Study 18 Years and older (Adult, Older Adult )

Sexes Eligible for Study All

Accepts Healthy Volunteers No

Not meaning to derail the thread, but ... What typo blew up the space shuttle? Challenger was lost when managers in a rush to launch overrode the recommendations of Thiokol engineers. Columbia was lost when a piece of insulation struck the leading edge of the left orbiter wing at launch and the risk to the shuttle was not recognized by those in charge.

Headline is incorrect; Rybelsus, an oral semaglutide, was approved in 2019. Maybe oral Wegovy is the first oral GLP-1 approved for obesity rather than diabetes.

It says the second dose was "injected."

There must be many thousands of people named Frank Miller, Jr. So something in addition to the name had to be used.

IIRC, on his deathbed he was complaining about the design of the hospital's suction catheters.

I see a flash of white text on a dark background, then "Application error: a client-side exception has occurred (see the browser console for more information)." in black on the same very dark background. Chrome on Win 10

My bad. I was thinking A, B, and C were integers.

That would seem to imply that for A =/= 0, C/A is irrational. This seems counterintuitive.

As others have mentioned, it's important to note that this is not a trial of ECMO vs no ECMO, but of immediate ECMO vs usual care including ECMO if needed, and that 39% of the control arm wound up receiving ECMO, which could have the effect of reducing apparent treatment benefit. Also, the 28% reduction in the primary endpoint could well reach statistical significance if the trial numbers were larger. Finally, this was for patients with cardiogenic shock, most likely predominantly heart attack patients. They likely represent a smallish portion of the patients who might be considered for ECMO, so one can't generalize to all scenarios.

This reminds me of a story from several years ago where, as part of a bike-a-thon to benefit Parkinson's research, a Parkinson's patient rode a tandem bike with a family member providing the pedal power. This "passive exercise" led to a several day remission of Parkinsonian symptoms. The current article would provide a plausible mechanism for this effect.